Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Forty51 Ventures
Deal Size : $3.5 million
Deal Type : Financing
Mysthera Therapeutics Launches to Develop First-in-Class Autoimmune Disease Therapies
Details : The capital will be used to advance its portfolio of pre-clinical stage, pan-PIM kinase inhibitors to uniquely modulate multi-lineage immune cell functions.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 21, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Forty51 Ventures
Deal Size : $3.5 million
Deal Type : Financing